PATENT CLAIM ANALYSIS

Application Number: 15970457
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-08
Patent Classification: ["544", "317000"]

Abstract:
Disclosed are substituted aromatic N-heterocyclic compounds. The disclosed compounds typically exhibit kinase inhibition activity, for example, and inhibit Mnk1 kinase and/or Mnk2 kinase. The disclosed compounds may be used in pharmaceutical compositions and methods for treating diseases or disorders associated with Mnk1 kinase activity and/or Mnk2 kinase activity, such as cancers, diabetes, autism, and fragile X syndrome.

Claim (Index 20):
The method of  claim 14 , wherein the disease or disorder associated with Mnk1 activity and/or Mnk2 activity is fragile X syndrome.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 93.0
- Lexical Diversity: 1.53488
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15337332', '15858733', '14527328', '15545598', '12378195']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8168996722416003
- 35 USC 102 Novelty (BERT): 0.5434871596712193
- Combined Prediction Score: 0.7895584209845623
- Mean Citation Score: 354.8572660000001
- Max Citation Score: 449.72232
- Similarity Product: 249.20332369608883

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test